Perspectives in HIV Protease Inhibitors
The therapy of HIV-1, the causative agent of AIDS, is limited today to a small number of different drugs, all of which are nucleoside analogues. Nucleoside analogues active against HIV are all inhibitors of reverse transcriptase (RT) and target primarily early events in the replication cycle of HIV. In vitro activity of these compounds has been confirmed by evidence of inhibition of HIV replication in vivo, although the clinical benefits of these compounds wane with time. Agents active against targets other than RT are necessary to expand and improve the pharmacopoeia for the treatment of HIV infection and AIDS. Specific inhibitors of the HIV protease promise to expand the options for the treatment of HIV infection.
KeywordsNucleoside Analogue Plasma Drug Level Human Immunodeficiency Virus Protease Peripheral Blood Mononuclear Cell Culture Active Human Immunodeficiency Virus
Unable to display preview. Download preview PDF.
- 2.Norbeck DW. Recent advances in anti-retroviral chemotherapy for AIDS. Annu Rep Med Chem 1989 1989; 25: 149–58.Google Scholar
- 10.Data on file, Abbott Laboratories.Google Scholar
- 11.Kempf DJ, Marsh KC, Denissen JF, et al. ritonavir is a potent inhibitor of human immunodeficiency virus protease with high oral bioavailability.Google Scholar
- 13.Personal communication, G. Drusano.Google Scholar